Ex-Director Alleges Off-Label Marketing Objections Led to Unjust Termination

In a recent development, the ex-Director of Government Sales for a major pharmaceutical corporation has alleged in a retrial lawsuit that his termination was the result of his objections to off-label marketing practices within his former company. He claims to have raised concerns that the business was illegally selling a pharmaceutical to federal healthcare providers for uses not approved by regulatory authorities.

The controversy around off-label marketing—promoting pharmaceuticals for unapproved uses—continues to be a contentious issue within the industry, inviting legal scrutiny and spurring heated debates about ethical practices.

More details about these allegations can be found in the original coverage of this lawsuit in this Law360 article.

Although common, off-label prescribing is a territory fraught with legal ambiguities. As such, lawsuits like these highlight the growing need for clarifications and tighter regulations from legal and healthcare bodies on sanctioned marketing practices within the pharmaceutical industry.